ONCOLife presents an exclusive interview with Dr. Miguel-Angel Perales, Co-Chair of the CAR T Vision initiative, as he shares ...

We’re honored to share our exclusive interview with Lorna Warick, CEO of Lymphoma Coalition. In this session, we explore the ...

Vividion Therapeutics and Bayer are advancing VVD-214, the world’s only clinical-stage covalent WRN inhibitor, for MSI-high cancers including colorectal, endometrial, ovarian, and gastric tumors.

In a significant development for the treatment of extensive-stage small cell lung cancer (ES-SCLC), the Phase III IMforte study has shown that the combination of Roche’s Tecentriq® (atezolizumab) with ...

Bayer announced new post-hoc analyses from the Phase III ARANOTE trial, showing that darolutamide (Nubeqa) plus androgen deprivation therapy (ADT) improved health-related quality of life (HRQoL) and ...

Presented at ASCO 2025, new data from the DESTINY-Breast09 trial showed that Enhertu plus pertuzumab cut the risk of disease progression or death by 44% compared to taxane, trastuzumab, and pertuzumab ...

BioNTech SE and Bristol Myers Squibb (BMS) have announced a global collaboration to jointly develop and commercialize BNT327, an investigational bispecific antibody that holds promise for treating a ...

A Canadian Cancer Society-funded trial shows a 3-year structured exercise program post-chemotherapy improves survival for colon cancer patients. Involving 889 participants, the trial saw a 28% ...

The first-in-human results for pasritamig, a bispecific T-cell engager, show promising Phase 1 data in heavily pretreated patients with metastatic castration-resistant prostate cancer (mCRPC).

Genentech announced positive final results for inavolisib from the Phase III INAVO120 study at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The data, also published in NEJM, ...

The new data from the Phase 3 C-POST trial presented at ASCO 2025 demonstrated that cemiplimab (Libtayo) reduced the risk of recurrence or death by 68% in high-risk cutaneous squamous cell carcinoma.